Verastem, Inc.
(NASDAQ : VSTM)

( )
VSTM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.37%86.271.3%$1352.68m
AMGNAmgen Inc.
0.97%203.881.2%$612.82m
GILDGilead Sciences, Inc.
0.77%69.180.9%$531.67m
LOXOLoxo Oncology Inc
0.11%233.5012.7%$525.80m
BIIBBiogen Inc.
-0.27%337.421.3%$408.79m
VRTXVertex Pharmaceuticals Incorporated
2.19%194.701.9%$323.01m
ILMNIllumina, Inc.
0.87%312.753.5%$317.65m
REGNRegeneron Pharmaceuticals, Inc.
0.35%418.842.6%$300.57m
ALXNAlexion Pharmaceuticals, Inc.
2.12%117.052.0%$212.97m
TSROTESARO, Inc.
0.03%74.9614.4%$167.91m
INCYIncyte Corporation
-0.32%78.422.5%$149.05m
AAgilent Technologies, Inc.
2.10%72.311.5%$147.46m
EXASExact Sciences Corporation
4.19%78.8025.3%$141.72m
SRPTSarepta Therapeutics, Inc.
1.22%122.8015.4%$135.00m
LGNDLigand Pharmaceuticals Incorporated
6.49%117.9023.1%$126.49m

Company Profile

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.